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The Retinoic acid-inducible gene I (RIG-I) receptor senses cytoplasmic viral RNA 24 
and activates type I interferons (IFN-I) and downstream antiviral immune responses. 25 
How RIG-I binds to viral RNA and how its activation is regulated remains unclear. 26 
Here, using IFI16 knockout cells and p204- deficient mice, we demonstrated that the 27 
DNA sensor IFI16 enhances IFN-I production to inhibit IAV replication. IFI16 28 
positively upregulates RIG-I transcription through direct binding to and recruitment of 29 
RNA Pol II to the RIG-I promoter. IFI16 also binds to influenza viral RNA via its 30 
HINa domain, and to RIG-I protein with its PYRIN domain, thus promoting 31 
IAV-induced K63- linked polyubiquitination and RIG-I activation. Our work 32 
demonstrate that IFI16 is a positive regulator of RIG-I signaling during influenza 33 
virus infection, highlighting its role in RLR-mediated innate immune response to IAV 34 
and other RNA viruses, and suggesting its possible exploitation to modulate the 35 
antiviral response. 36 











Influenza virus is one of the most important causes of respiratory tract infection, 46 
resulting in at least 26 million influenza illnesses, 250,000 hospitalizations and 14,000 47 
deaths during the 2019-2020 season in the United States 48 
(https://www.cdc.gov/flu/season/index.html). A(H1N1)/pdm2009, H3N2, and 49 
influenza B (B/Yamagata or B/Victoria lineage) viruses are mainly responsible for 50 
seasonal influenza epidemics each year. Moreover, avian influenza virus remains a 51 
significant additional threat to human health, in particular the H5, H7 and H9 52 
subtypes. Although vaccination is the most effective way to control IAV, prediction of 53 
evolving immunogenic epitopes as well as challenges of vaccine production and 54 
distribution often limit vaccine efficacy and availability. Furthermore, antiviral 55 
resistant IAV strains continued to be identified; they include H274Y mutation in the 56 
neuraminidase (NA)1,2, and three major mutations (L26F, V27A, and S31N) in the M2 57 
protein3,4. Hence, the development of effective interventions against influenza virus 58 
infection remains an outstanding public health need. Targeting an essential host factor 59 
critical for influenza infection is a promising antiviral strategy5.  60 
Several families of pattern recognition receptors (PRRs) have been described: 61 
toll like receptors (TLRs), retinoic acid inducible gene-I (RIG-I) receptors (RLRs) and 62 
nucleotide oligomerization domain (NOD)-like receptors (NLRs) are involved in the 63 
recognition of influenza viruses6-8. Among them, RIG-I is thought to be the most 64 
important sensor of influenza virus9; it binds the 5’ppp-RNA of the virus, leading it to 65 
undergo conformational changes and exposing its caspase activation and recruitment 66 
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domains (CARDs)10, which is then ubiquitinated by the action of E3 ligases such as 67 
tripartite motif 25 (TRIM25)11 and RIPLET12. TRIM25 activates RIG-I through the 68 
generation of unanchored K63-linked polyubiquitin chains interacting with the 69 
CARDs13, or through the generation of anchored K63-linked polyubiquitin chains 70 
attached to lysine 172 of RIG-I11. This process results in the interaction of RIG-I with 71 
the mitochondrial antiviral signaling (MAVS) adaptor, which leads to the subsequent 72 
activation of IRF3/7 and NF-κB and thereby inducing the expression of IFN-I and 73 
pro-inflammatory cytokines14. Therefore, RIG-I activation has to be tightly regulated 74 
to ensure effective virus inhibition with minimal excessive inflammatory response.  75 
Interferon-γ-inducible protein-16 (IFI16) is a member of the pyrin and HIN 76 
domain (PYHIN) containing protein family, which encodes a class of homologous 77 
proteins that share a 200-amino acid signature motif (HIN)15. IFI16 was first reported 78 
as a sensor of transfected and viral DNA involved in innate signaling16,17 and 79 
functions as an innate immune sensors in eukaryotic cells18-24. IFI16 senses the 80 
double-stranded DNA (dsDNA) from invading DNA viruses including herpes simplex 81 
virus 1 (HSV-1), Kaposi sarcoma-associated herpesvirus (KSHV), vaccinia virus 82 
(VACV)21,24,25, the single-stranded DNA (ssDNA) from HIV-infected CD4+ T cells 83 
and nuclear damaged DNA from etoposide-treated keratinocytes22,26. DNA 84 
recognition by IFI16 induces the activation of the stimulator of interferon 85 
genes-TANK-binding kinase 1-interferon regulatory factor 3 (STING-TBK1-IRF3) 86 
pathway, leading to the induction of IFN-I or ASC-caspase 1-dependent 87 
inflammasome to produce interleukin-1β (IL-1β)21,24,26. Additionally, a role for IFI16 88 
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in RNA virus infection has been identified; IFI16 transcriptionally regulates the IFN-I 89 
gene expression in Sendai virus infection27. The murine ortholog of IFI16 (p204) is 90 
highly induced in mouse hepatitis coronavirus infection and inhibits IRF7-mediated 91 
IFN-I production28. Moreover, it was shown that IFI16 interacts with MAVS to 92 
promote MAVS-mediated production of IFN-I that inhibits porcine reproductive and 93 
respiratory syndrome virus 2 replication29. More recently, IFI16 was found to directly 94 
bind Chikungunya virus (CHIKV) genome RNA and restrict viral replication and 95 
maturation30, which further suggests that IFI16 may play a crucial role in RNA virus 96 
infection. However, the precise role of IFI16 in influenza virus infection has not been 97 
elucidated.  98 
Here, we showed that IFI16, which was identified as an influenza viral RBP, was 99 
highly induced both in vitro and in vivo during IAV infection. We further 100 
demonstrated that IFI16 upregulated RIG-I transcription by binding its HINa domain 101 
to the RIG-I promoter, and interacted with both IAV vRNAs and RIG-I to promote 102 
influenza virus-induced K63-linked polyubiquitination of RIG-I. Collectively, these 103 
results indicate that IFI16 is a key positive regulator of RIG-I signaling in antiviral 104 









IFI16 is a viral RBP involved in influenza virus infection 112 
Owing to its RNA genome, influenza virus utilizes RNA-binding proteins (RBPs) 113 
of both viral and host origin for its replication. To uncover comprehensive viral RNA 114 
(vRNA)-host protein interactions, we performed affinity purification coupled with 115 
mass spectrometry (AP-MS) analysis of influenza vRNA complexes. The eight vRNA 116 
segments of H7N9 virus were individually transcribed and labeled with biotin in vitro, 117 
and incubated with lysates from IAV virus-infected THP-1 cells. vRNA complexes 118 
bound to streptavidin magnetic beads were analyzed by mass spectrometry (Fig.1A). 119 
Domain enrichment analysis of co-purified proteins for each RNA bait revealed that 120 
more than 90% of the isolated proteins harbored nucleic acid binding domains 121 
(Fig.1B). We identified 70 candidate vRNA-binding proteins that could bind to no 122 
less than 3 baits. A high number of co-purified proteins have been reported as RBPs, 123 
such as PTBP131, TRA2B32, DDX533, DDX3X34, and RBBP635, which indicates that 124 
our approach was effective in identifying vRNA-interacting proteins for influenza 125 
virus. Expression results demonstrated that IFI16 was most highly expressed for the 126 
duration of IAV infection (Fig.1C) which suggests that IFI16 may play an important 127 
role in IAV infection. 128 
To determine whether IFI16 is involved in IAV replication, we first evaluated 129 
IFI16 expression in PR8-infected human cells. IFI16 mRNA level was significantly 130 
upregulated in THP-1, A549 and HEK293 cells during PR8 infection (Extended Data 131 
Fig.1A-C). We also found that PR8 infection significantly elevated p204 expression in 132 
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mice lung tissues at 1 day post infection (dpi), 3 dpi and 5 dpi (Extended Data Fig.1D). 133 
PR8 virus actively induced the expression of IFI16 in THP-1 (Extended Data Fig.1E) 134 
and A549 cells (Fig.1D) cells. Furthermore, UV-inactivated PR8 virus did not induce 135 
IFI16 expression in A549 cells compared with live virus infection (Extended Data 136 
Fig.1F-G). Collectively, the findings suggest that IFI16 is involved in the modulation 137 
of influenza virus infection.  138 
In uninfected cells, IFI16 was mainly localized in the nucleus; PR8 infection 139 
induced accumulation of IFI16 in the nucleus and cytoplasm (Fig.1E-F). Consistent 140 
with the immunostaining results, PR8 virus infection caused build-up of IFI16 protein 141 
in the cytoplasm and nucleus (Extended Data Fig.1H). And treatment of A549 cells 142 
with human IFN-γ or Poly(I:C) also induced IFI16 accumulation in the nucleus and 143 
cytoplasm (Extended Data Fig.1I-K). It was reported that acetylation of IFI16 144 
modulates its cellular distribution and cytoplasm translocation in DNA virus 145 
infection25,36. During IAV infection, we also detected the acetylation of IFI16 in PR8 146 
virus-infected A549 cells at 12 and 24 hpi (Fig.1G, Extended Data Fig.1L). 147 
Additionally, low levels of nuclear acetylated IFI16 PLA dots were detected in 148 
uninfected A549 cells (Fig.1H). In contrast, acetylated IFI16 dots were clearly 149 
elevated in the nucleus and cytoplasm at 24 hpi (Fig.1H). We found that IAV-induced 150 
accumulation of IFI16 into the cytoplasm was abolished in C646-treated cells 151 
(Extended Data Fig.1M). Collectively, IFI16 is highly upregulated during IAV 152 
infection and whose associated acetylation could confer functional modification such 153 
as stabilization of IFI16 protein.   154 
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IFI16 inhibits IAV infection in vitro and in vivo 155 
To determine the impact of IFI16 on influenza virus, IFI16-Flag vectors were 156 
transfected into A549 cells followed by PR8 infection at 1.0 MOI. Overexpression of 157 
IFI16 significantly reduced viral titers of PR8 at 18 hpi (Fig.2A) and reduced the 158 
expression of viral NP and M1 proteins (Fig.2B). Increasing the amounts of 159 
transfected IFI16-Flag vectors in HEK293T-Gluc cells resulted in impaired viral 160 
replication in a dose-dependent manner (Fig.2C). In addition, overexpression of IFI16 161 
inhibited the expression of mRNA and vRNA of NP and M1 genes in A549 cells 162 
(Extended Data Fig.2A), and protein levels of NP at 6, 12 and 18 hpi in HEK293 cells 163 
(Extended Data Fig.2B). Conversely, when IFI16 was knockdown by siRNA in A549 164 
cells, there were significant increases in viral protein and titer of progeny viruses 165 
(Extended Data Fig.2C-D). To investigate the function of endogenous IFI16 during 166 
IAV infection, IFI16+/+ and IFI16-/- A549 cells were infected with PR8 virus. Infected 167 
IFI16-/- A549 cells produced higher viral titers at 12 and 24 hpi (Fig.2D) and protein 168 
levels of viral NP and M1 at 12 and 18 hpi (Fig.2E). In a gain-of-function experiment, 169 
exogenous expression of IFI16 in IFI16-/- A549 cells effectively reduced the 170 
expression of viral NP and M1 proteins at 12 and 18 hpi (Fig.2F). Accordingly, we 171 
found that the replication of GFP-tagged PR8 virus was markedly increased in IFI16-/- 172 
A549 cells compared with IFI16+/+ A549 cells (Fig.2G). Collectively, these findings 173 
indicate that IFI16 inhibits influenza virus replication in human cells. 174 
Additionally, PR8-infected WT mice suffered significantly less weight loss than 175 
p204-deficient (KO) mice, and started to regain body weight by 8 dpi (Fig.3A). 176 
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Consequently, survival rate of PR8 infected p204-/- mice was significantly poorer than 177 
infected WT mice (Fig.3B), which suggests that control of IAV infection in vivo also 178 
requires p204. In lung tissues of KO mice, PR8 virus replication at 4 and 6 dpi was 179 
higher (Fig.3C), with accompanying greater viral NP mRNA and vRNA levels 180 
(Fig.3D), in lung tissues of KO mice than in corresponding WT mice. Moreover, viral 181 
NP staining was more intense in lung sections of KO mice at 5 dpi than in 182 
corresponding WT mice (Fig.3E). Notably, gross- and histo-pathology revealed that 183 
lung tissues of PR8 virus-infected KO mice displayed more extensive damage at 3 184 
and 5 dpi (Fig.3F), and more severe inflammatory damage at 3 dpi (Fig.3G), than in 185 
corresponding WT mice. Accordingly, IL-6 and MCP-1 proteins in BALFs were also 186 
significantly higher in PR8-infected WT mice than those found in corresponding 187 
p204-/- mice (Fig.3H-I). Furthermore, p204 deficiency dramatically inhibited their 188 
transcription: IFN-β, viperin, OAS1, ISG15 and IL-6 in PR8 virus-infected BMDMs 189 
(Fig.3J-N). Therefore, IFI16 is required for host defense against influenza virus 190 
infection in vitro and in vivo. 191 
IFI16 enhances the production of IFN-I in IAV infection  192 
DNA recognition by IFI16 induces the activation of STING-TBK1-IRF3 193 
pathway, leading to the induction of IFN-I21,24,26. To investigate innate immune 194 
activation by IFI16, we performed transcriptomic analysis in IFI16+/+ and IFI16-/- 195 
A549 cells infected with PR8 virus for 12 h. In GO-term enrichment analysis, 10 196 
enriched terms identified were related to antiviral responses (Fig.4A). The number of 197 
genes associated with individual terms as well as enrichment probability were lower 198 
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in IFI16-/- A549 cells (Fig.4A). Sixteen ISGs were found to be exclusively 199 
upregulated in IFI16+/+ cells during IAV infection, while only 4 ISGs were 200 
upregulated in IFI16-/- A549 cells (Fig.4B). Collectively, these results show that the 201 
induction of ISGs was reduced in the absence of IFI16. We next evaluated the 202 
function of IFI16 in the induction of IFN-I. RT-qPCR analysis showed that 203 
overexpression of IFI16 enhanced PR8 virus-induced expression of IFN-β, ISG15 and 204 
IL-6 at 6 and 12 hpi (Extended Data Fig.3A-C). Conversely, IFI16 deficiency greatly 205 
reduced the PR8 virus-induced expression of IFN-β, RIG-I, ISG56, and viperin 206 
(Fig.4C-F) as well as IFN-α4, IRF7 and CXCL5 (Extended Data Fig.3D-F) in A549 207 
cells. Furthermore, overexpression of IFI16 in A549 cells increased PR8 208 
virus-induced IFN-β protein production at 12 and 18 hpi in a dose-dependent manner 209 
(Fig.4G), while IFI16 deficiency markedly decreased IFN-β production (Fig.4H), 210 
which suggest that IFI16 mediates antiviral effects through influenza virus-induced 211 
IFN-I signaling.  212 
To examine the contribution of IFI16 to the RIG-I signaling, we transfected 213 
IFI16-Flag or control plasmids into A549 cells followed by infection with PR8 virus 214 
at 1.0 MOI. Overexpression of IFI16 in infected cells enhanced protein detection of 215 
RIG-I, phosphorylated (p)-TBK1, p-IRF3 and p-P65 relative to infected controls 216 
(Fig.4I). In contrast, deficiency of IFI16 in infected cells led to reduced protein 217 
detection of RIG-I, p-TBK1 and p-IRF3 compared with the IFI16+/+ group (Fig.4J). 218 
Consistent with these results, overexpression of IFI16 in the presence of 5’ppp-RNA 219 
also increased protein detection of RIG-I, p-TBK1 and p-IRF3 (Extended Data 220 
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Fig.3G). Furthermore, exogenous expression of IFI16 in infected IFI16-/- A549 cells 221 
restored the protein expression of RIG-I, p-TBK1 and p-IRF3 (Extended Data Fig.3H). 222 
Immunofluorescence results showed that IFI16 deficiency reduced the level of p-IRF3 223 
(Ser396) in nuclear in PR8 virus-infected A549 cells (Fig.4K-L). Taken together, 224 
these findings indicate that IFI16 is a potent stimulator of the IFN-I response in 225 
influenza virus infection. 226 
IFI16 transcriptionally upregulates the expression of RIG-I 227 
Overexpression of IFI16 progressively upregulated RIG-I protein expression in 228 
A549 cells in a time-dependent manner (Fig.5A) and in a dose-dependent manner 229 
(Extended Data Fig.4A). HEK293 cells co-transfected with IFI16-Myc and 230 
RIG-I-Flag followed by cycloheximide (CHX) treatment did not exhibit evidence of 231 
RIG-I protein degradation (Extended Data Fig.4B). And overexpression of IFI16 also 232 
increased protein and mRNA expression of RIG-I in ifnar1-/-A549 cells in a 233 
dose-dependent manner (Extended Data Fig.4C-4D). Furthermore, A549 cells 234 
transfected with IFI16-Flag vectors showed rising levels of RIG-I mRNA in a 235 
vector-dose dependent manner (Extended Data Fig.4E) and a progressive 236 
time-dependent manner (Fig.5B). Consistent with the findings in A549 cells, mRNA 237 
expression of RIG-I in PR8 virus infected lung tissues of p204-deficient (KO) mice 238 
was significantly reduced at 1 and 3 dpi compared with corresponding WT mice 239 
(Extended Data Fig.4F). Taken together, our results indicate that IFI16 upregulates 240 
RIG-I from the transcriptional level. 241 
To further assess the role of IFI16 in the regulation RIG-I, luciferase reporter 242 
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vector driven by a RIG-I promoter was used in transfections of HEK293 cells. The 243 
RIG-I promoter was responsive to IFI16 overexpression in a vector-dose dependent 244 
manner (Fig.5C), which indicates that IFI16 is capable of transactivating the RIG-I 245 
promoter.  246 
To determine the minimum promoter length of RIG-I that is responsive to the 247 
IFI16 induction, an extensive series of RIG-I promoter deletion constructs, each 248 
spliced to luciferase reporter gene, were generated for co-transfections with increasing 249 
amounts of IFI16-Flag expression vectors (Fig.5D-I). The minimum RIG-I promoter 250 
responsive to IFI16-Flag overexpression was found to be between -371 to -360 bp in 251 
length (Fig.5I). Furthermore, Flag antibody pull down experiments, based on a series  252 
biotinylated double-stranded DNA probes that spanned the minimum promoter 253 
section (Extended Data Fig.4G), found that only probe p2-mut4 which harbored 254 
mutations between the -371 to -360 region of the promoter failed to bind IFI16-Flag 255 
(Extended Data Fig.4H). ChIP-qPCR assays, using two sets of primer pairs that target 256 
the -500 to -250 bp region of RIG-I promoter, further demonstrated direct binding of 257 
IFI16 to the RIG-I promoter (Fig.5J). Collectively, IFI16 is capable of binding to the 258 
RIG-I promoter to promote RIG-I transcription. 259 
Next, to determine whether IFI16 affects the recruitment of RNA Pol II to the 260 
RIG-I promoter, chromatin immunoprecipitation was performed with Pol II antibody 261 
on IFI16+/+ and IFI16-/- A549 cells, infected with PR8 virus at 1.0 MOI for 0 and 12 h. 262 
qPCR targeting the detection of the basal promoter site of RIG-I showed more RNA 263 
Pol II binding to the basal promoter of infected IFI16+/+ than infected IFI16-/- A549 264 
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cells (Fig.5K), but no significant difference on the GAPDH promoter (Extended Data 265 
Fig.4I), suggesting that during infection IFI16 facilitates RNA Pol II recruitment to 266 
the basal promoter of RIG-I.  267 
To investigate the domain(s) in IFI16 responsible for activating RIG-I  268 
transcription, we constructed IFI16 expression mutants bearing different domain 269 
deletions (Extended Data Fig.4J). Mutants without the HINa domain completely lost 270 
the ability to activate the RIG-I-luc reporter gene (Fig.5L). In a separate experiment, 271 
we also found that in the absence of the HINa domain there was no binding of IFI16 272 
to biotinylated RIG-I promoter (Extended Data Fig.4K). Deletion of HINa domain in 273 
IFI16 abrogated its antiviral activity in response to PR8 virus infection (Extended 274 
Data Fig.4L). Taken together, IFI16 binds RIG-I promoter with its HINa domain 275 
facilitating the recruitment of RNA Pol II to the site, thereby enhancing the 276 
transcriptional activation of RIG-I.  277 
IFI16 binds vRNAs and interacts with RIG-I 278 
Since IFI16 is also a RBP, we determined if IFI16 binds vRNAs as with RIG-I 279 
promoter. Pull down assays using cell lysates of HEK293 cells, separately 280 
overexpressing Flag-tagged IFI16, RIG-I, MDA-5 and TBK1 proteins, incubated with  281 
biotinylated NP vRNA showed binding of IFI16, RIG-I and MDA-5 to the vRNAs 282 
(Extended Data Fig.5A). MST results showed that the HINa domain also exhibited 283 
high affinity for full-length NS vRNA (Extended Data Fig.5B). To further 284 
demonstrate binding between IFI16 and other IAV RNAs, purified GST-IFI16 285 
proteins were incubated with fluorescein-labeled HA, NP, PA and PB2 vRNAs. MST 286 
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assays also showed IFI16 binding with the different vRNAs (Extended Data Fig.5C). 287 
Furthermore, RNA FISH analysis revealed increasing co-localization of IFI16 with 288 
NP vRNA in PR8 virus-infected A549 cells at 6 and 12 hpi (Fig.6A). To identify 289 
bound vRNAs during infection, RNA eluted from co-precipitation of IFI16-Flag from 290 
IAV-infected RIG-I-/- cells was subjected to deep sequencing analysis which detected 291 
IFI16 binding to all eight IAV gene segments (Fig.6B). RIG-I has been found with 292 
IAV genomic fragments37. IFI16 was also specifically enriched in genomic IAV 293 
segments during infection (Fig.6B). Importantly, only wild-type IFI16 and IFI16 294 
mutants bearing the HINa domain associated with vRNA fragments during infection 295 
(Fig.6C, Extended Data Fig.5D-E). Taken together, these results indicate that during 296 
infection IFI16 can directly bind viral genome RNAs via its HINa domain. 297 
To determine if IFI16 is involved in the recognition of vRNAs by RIG-I during 298 
influenza virus infection, co-IP assays were performed that demonstrated the 299 
endogenous interaction of IFI16 and RIG-I during PR8 virus infection in A549 cells 300 
(Fig.6D-E). Furthermore, in situ PLA microscopy showed co-localization of IFI16 301 
and RIG-I in the cytoplasm of PR8 virus-infected A549 cells (Fig.6F). Consistent with 302 
PLA results, confocal microscopy also found increasing interaction between IFI16 303 
and RIG-I during IAV infection (Extended Data Fig.5F). The PYRIN domain can 304 
mediate the interaction between IFI16 and host proteins38,39. The IFI16-ΔPYRIN-GFP 305 
mutant was unable to co-localize with RIG-I in HEK293 cells, indicating that the 306 
PYRIN domain is required in the protein-protein interaction (Extended Data Fig.5G). 307 
Interestingly, PYRIN-GFP transfection into HEK293 cells resulted in its protein 308 
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co-localization with RIG-I that formed filamentous structures (Extended Data Fig.5H 309 
-I). IFI16 filamentous structures are involved in antiviral responses by associating 310 
with host restriction factors40-42. Collectively, these findings indicate that IFI16 binds 311 
influenza viral RNAs and associates with RIG-I in influenza virus-infected cells.  312 
RIG-I is required for IFI16-mediated antiviral response in IAV infection 313 
K63-linked polyubiquitination of RIG-I by TRIM25 is essential for its 314 
activation11. To explore the potential role of IFI16 in the promotion of RIG-I signaling, 315 
we examined the interaction between TRIM25 and RIG-I in PR8 virus-infected 316 
IFI16+/+ and IFI16-/- A549 cells. Co-IP and in situ-PLA experiments indicated that 317 
IFI16 deficiency impaired the interaction and co-localization between RIG-I and 318 
TRIM25 due to their reduced expression in infected IFI16-/- cells, and inhibited 319 
K63-linked ployubiquitination of RIG-I during virus infection (Extended Data 320 
Fig.6A-B, 7A). To further determine the impact of IFI16 on RIG-I polyubiquitination, 321 
we transfected HEK293 cells with Myc control or IFI16-Myc, RIG-I-Flag, 322 
TRIM25-His and either HA-ubiquitin, HA-ubiquitin-K48 or HA-ubiquitin-K63 323 
plasmids. Co-IP experiments showed that IFI16 remarkably enhanced the interaction 324 
between TRIM25 and RIG-I and promoted RIG-I polyubiquitination in the presence 325 
of HA-ubiquitin and HA-ubiqutin-K63, but not HA-ubiquitin-K48 (Extended Data 326 
Fig.7B). Thus, IFI16 facilitates TRIM25 binding to RIG-I  and consequently 327 
promotes K63-linked polyubiquitination of RIG-I. RIP-RT-qPCR assays showed that 328 
overexpression of IFI16 significantly enhanced the RIG-I binding to PA vRNA 329 
(Extended Data Fig.7C). And correspondingly, IFI16 deficiency also markedly 330 
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reduced RIG-I binding to PA vRNA in PR8 virus-infected A549 cells (Extended Data 331 
Fig.7D). RIP-EMSA and RNA pull-down experiments further demonstrated that the 332 
binding of PA vRNA with RIG-I is sharply increased with increasing amount of IFI16 333 
(Extended Data Fig.6C-6D). Furthermore, RNA co-purified with RIG-I by RIP 334 
analysis from IAV-infected IFI16+/+ cells could induce the production of IFN-β more 335 
effectively than that from IFI16-/- cells (Extended Data Fig.7E-F), suggesting that 336 
IFI16 facilitates the stable binding of RIG-I to vRNAs during IAV infection. 337 
Importantly, only wild-type IFI16 and IFI16 mutants bearing HINa and PYRIN 338 
domain, but not HINb, promoted vRNA binding to RIG-I (Extended Data Fig.6E) and 339 
enhanced the production of IFN-β during IAV infection (Extended Data Fig.6F). 340 
Consistent with these observations, IFN-β reporter assays showed that overexpression 341 
of IFI16 significantly enhanced PR8 virus-induced expression of IFN-β-luciferase 342 
reporter genes (Extended Data Fig.7G). Moreover, RIG-I-induced activity of 343 
IFN-β-luciferase reporter rose with increasing amounts of IFI16 expression vectors 344 
used in transfections (Extended Data Fig.7H). Taken together, these results suggest 345 
that IFI16 promotes the activation of RIG-I signaling and in so doing, boosts the 346 
production of IFN-I. 347 
Finally, to investigate whether antiviral function of IFI16 in IAV infection is 348 
dependent on RIG-I, A549 cells were transfected with the RIG-I- or MAVS-targeting 349 
siRNAs and then infected with IAV. Western blotting showed that the level of RIG-I 350 
or MAVS was significantly reduced by RIG-I-targeting siRNA#2835 (Extended Data 351 
Fig.7I) or MAVS-targeting siRNA#571 transfection (Extended Data Fig.6G). IAV 352 
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infection could not effectively stimulate the production of IFN-β in RIG-I- or 353 
MAVS-silenced IFI16+/+ A549 cells (Extended Data Fig.6H, 7J). Overexpression of 354 
IFI16 in RIG-I- or MAVS-silenced A549 cells could not induce the production of 355 
IFN-β during IAV infection (Extended Data Fig.6I, 7K). Additionally, RIG-I-/- 356 
HEK293 cells were transfected with IFI16-Flag or Flag vectors and then infected with 357 
PR8 virus at 1.0 MOI. Overexpression of IFI16 failed to inhibit viral NP and M1 358 
replication in PR8 virus-infected RIG-I-/- cells at 6 and 12 hpi (Extended Data Fig.7L), 359 
whereas exogenous expression of RIG-I in RIG-I-/- cells rescued the inhibitory effect 360 
of IFI16 on viral titers at 24 hpi (Extended Data Fig.7M). Taken together, our results 361 
















Host cells possess critical sensors that can discriminate viral and host nucleic 376 
acids. IFI16 has been demonstrated to be a sensor of viral DNA in innate immune 377 
signaling16,17. However, its role in sensing viral RNA during infection, in particular 378 
influenza virus infection, hitherto is unknown. In this study, we demonstrated that 379 
IFI16 is a viral RBP and is induced during influenza virus infection. IFI16 inhibited 380 
influenza virus replication in human cell lines and in mice through enhanced the 381 
induction of IFN-I. IFI16 enhances the transcription of RIG-I, binds viral RNAs and 382 
interact with RIG-I protein, thereby increasing the sensitivity of RIG-I signaling. 383 
These findings establish a critical role for IFI16 in antiviral innate immune response 384 
to influenza virus and possibly other RNA viruses (a proposed signaling model is 385 
depicted in Extended Data Fig. 8).  386 
We found that IFI16 was strongly induced by IAV, which is consistent with 387 
previous findings that IFI16 could be induced by RNA viruses infection and be 388 
upregulated by the type I and type III interferons as an ISG27-29. IFI16 is known to 389 
boost sensing of intracellular DNA and subsequent IFN-I induction21,24,26; it functions 390 
as a cytoplasmic immune sensor-mediating pyroptotic death of tissue CD4+ T cells 391 
abortively infected with HIV-122. Thus, the main role of IFI16 had been assumed to be 392 
a cytoplasmic sensor of viral DNA43. However, this is at odds with the findings that 393 
IFI16 is predominantly localized in the nucleus36. We found that IFI16 is induced in 394 
the nucleus and acts as a positive transcriptional regulator of RIG-I during IAV 395 
infection. These results confirm previous findings that IFI16 regulates RNA 396 
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virus-mediated IFN-I responses as a transcriptional factor 27. We also found that IFI16 397 
was induced in the cytoplasm, sensed and interacted with influenza viral RNAs, 398 
which is consistent with recent findings that IFI16 directly binds to incoming 399 
Chikungunya virus genome RNA and acts as a PRR30. Overexpression of IFI16 in 400 
cells significantly increased IFN-β expression and reduced in viral titers, whereas 401 
knockdown or knockout of IFI16 had the opposite effects, suggesting IFI16 is an 402 
important antiviral factor in IAV infection. Therefore we demonstrate an important 403 
mechanism of IFI16 in RLR-mediated antiviral innate immune response to influenza 404 
virus and further our understanding of the role of IFI16 in innate immunity.  405 
Viral RNA sensor RIG-I is thought to be the most important sensor of influenza 406 
virus infection9 in the recognition of cytoplasmic dsRNA leading to the transcriptional 407 
activation of IFN-I and downstream ISGs14. Thus, identification of positive regulators 408 
of RIG-I could be important in the control of virus infection. DNA-dependent 409 
activator of IFN-regulatory factor (DAI), a cytosolic DNA sensor, has already been 410 
found to recognize genomic RNA and regulate virus-induced cell-death pathways and 411 
thereby plays an important role in the pathogenesis of IAV infection44,45. Here, we 412 
demonstrated that IFI16 binds to viral RNAs and enhances RIG-I-mediated 413 
production of IFN-I during IAV infection. We further identified that IFI16 interacted 414 
with RIG-I that involves the PYRIN domain of IFI16. An interaction of IFI16 with 415 
RIG-I as a complex via siRNA was previously reported46. Notably, we found that 416 
IFI16 facilitates RIG-I binding to IAV vRNAs during infection and promotes 417 
virus-induced K63-linked polyubiquitination of RIG-I, indicating that IFI16 positively 418 
20 
 
contributes to RIG-I-dependent antiviral responses. Presently, it is not clear if the 419 
filamentous structures of IFI16 are necessary for IFI16-vRNAs and IFI16-RIG-I 420 
interactions, or about the types of viral RNA structures that are needed to interact with 421 
IFI16.  422 
Collectively, our study shows that IFI16 induced by influenza virus infection 423 
positively regulates the RIG-I signaling by enhancing its transcriptional expression  424 
through recruitment of RNA Pol II to the RIG-I promoter, and sensing of viral RNA to 425 
promote virus-induced K63-linked polyubiquitination of RIG-I. This study highlights 426 
an important mechanism of IFI16 in RLR-mediated innate antiviral immune response 427 
to IAV and possibly other RNA viruses infection, and expands our understanding of 428 
the functions of the innate immune system in intracellular virus recognition which 429 













Materials and Methods 441 
Ethics statement 442 
All animal experiments were performed in accordance with institutional 443 
guidelines of China Agricultural University (CAU) (approval SKLAB-B-2010-003) 444 
and approved by the Beijing Association for Science and Technology of China 445 
(approval SYXK, Beijing, 2007-0023).  446 
Cells 447 
Madin-Darby canine kidney cells (MDCK), human embryonic kidney cells 448 
(HEK293), and human lung adenocarcinoma epithelial cells (A549) were maintained 449 
in-house. THP-1 cell line was kindly provided by Dr. Shijun Zheng (China 450 
Agricultural University). IFI16-/- A549 and RIG-I-/- HEK293 cell lines were 451 
generously given by Dr. Yu Chen (Sun Yat-sen University) and Dr. Wenjun Liu 452 
(Institute of Microbiology, Chinese Academy of Sciences), respectively. Ifnar1-/- A549 453 
cell line was generously given by Dr. Ying Zhu (Wuhan University). And 454 
2fTGH-ISRE cell line was kindly provided by Dr. Fuping You (Peking University)47. 455 
HEK293T-Gluc cells were kindly provided by Dr. Shan Cen (Chinese Academy of 456 
Medical Sciences and Peking Union Medical School)48. Primary bone 457 
marrow-derived macrophages (BMDMs) were produced as described49. Cells were 458 
cultured in DMEM supplemented with 10% (v/v) heat-inactivated fetal bovine serum 459 
(FBS; Gibco), 100 U/mL penicillin and 100 μg/mL streptomycin.  460 
Viruses 461 
Influenza A/Puerto Rico/8/1934 (PR8; H1N1) strain was maintained in our 462 
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laboratory. PR8-GFP virus was generated by insertion of GFP CDS sequences at the 463 
carboxyl terminal of NS1 as described previously50. The methods of cell culture, mice 464 
infection, and virus titration in lung tissues were performed as previously described49.   465 
Plasmids construction and transfection 466 
IFI16, RIG-I, TBK1, TRIM25 and MAVS genes were amplified by PCR using 467 
PR8 virus-infected THP-1 cells at 8 hours post-infection (hpi). Full-length and 468 
mutated IFI16 expression constructs were generated using PRK5 containing different 469 
tags or pCDNA3.1-GFP vectors by recombinase-mediated recombination. Full-length 470 
RIG-I expression vectors were created using PRK5-Flag or pCDNA3.1-mCherry 471 
vectors. Full promoter sequences or truncations of RIG-I were generated using 472 
PGL3.0 luciferase reporter (Promega). Plasmids transfection experiments in HEK293 473 
or A549 cells were performed using Lipofectamine 3000 reagents (Invitrogen). 474 
IFI16+/+ or IFI16-/- A549 cells were transfected with indicated siRNAs using 475 
Lipofectamine RNAiMAX reagents (Invitrogen, Carlsbad, CA, USA). 476 
In vivo virus infection 477 
p204-deficient (p204-/-) mice were kindly provided by Dr. Wei Tang (Shandong 478 
University). Sex- and age-matched C57BL/6 mice were purchased from department 479 
of Laboratory Animal of Charles River, Beijing. Seven-weeks-old mice were 480 
inoculated intranasally with PR8 virus at a dose 50 TCID50 in 50 μL of 481 
phosphate-buffered saline (PBS). Body weight and survival were monitored daily 482 
after infection. Lung tissue lysates were generated by homogenizing snap-frozen lung 483 
tissues 2 times (20 second each time) in MEM medium, and centrifuging the lung 484 
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suspensions at 2000 rpm for 15 min. TCID50 assays were performed on MDCK cells 485 
and TCID50 values were calculated as previously described
49. WT and p204-/- mice 486 
were inoculated intranasally with PR8 virus at a dose 100 TCID50. The 487 
bronchoalveolar fluid (BALF) was collected at 0 and 3 dpi. The BD™ CBA Mouse 488 
Inflammation Kit (BD Biosciences, #552364) was used to quantitatively measure the 489 
IL-6 and MCP-1 levels in BALF. 490 
Antibodies and reagents 491 
Anti-IFI16 (ab191211), anti-TBK1 (ab40676), anti-NP (ab104870), anti-TBK1 492 
(ab40676), anti-Ubiquitin (linkage-specific K63) (ab271929) and anti-RNA 493 
polymerase II (ab5095) antibodies were from Abcam. Anti-IFI16 (sc-8023) and 494 
anti-TRIM25 (sc-166926) antibodies were from Santa Cruz. Rabbit anti-p65 495 
(#10745-1-AP), anti-HA (#66006-2-Ig) and anti-RIG-I (#20566-1-AP) antibodies 496 
were from Proteintech. Anti-IRF3 (YT2398) antibody was from ImmunoWay 497 
Biotechnology Company. Anti-Phospho-TBK1 (Ser172; #5483); anti-Phospho-IRF3 498 
(Ser396; #4947), anti-IFI16 (#14970S), anti-FLAG (#8146), anti-His (#9991) 499 
anti-Myc (#2278); anti-Phospho-p65 (Ser536; #3033) antibodies were from Cell 500 
Signaling Technology Inc.; Poly(I:C) (TLRL-PIC) was from InvivoGen. Recombinant 501 
human interferon-gamma (IFN-γ) (HY-P7025) and C-646 (HY-13823, 10 mg) was 502 
from MedChemExpress. 503 
In vitro transcription and biotin-labeling RNA purification 504 
Templates for T7 RNA transcription were linearized from H7N9 pSPT9 plasmids 505 
coding for individual RNA segments of H7N9 virus. T7 transcription reactions were 506 
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carried out with T7 RNA polymerase in transcription buffer and biotin-dNTPs mix 507 
according to manufacturer’s instructions (Promega)51. Following DNase I treatment, 508 
biotin-labeled vRNAs were extracted with phenol/chloroform, ethanol precipitated 509 
and purified with RNAeasy columns (Aidlab Biotechnologies) and analyzed on 510 
denaturing agarose gels for correct size. 511 
Affinity purification coupled with mass spectrometry (AP-MS) 512 
THP-1 cells were treated with phorbolmyristateacetate (PMA) for 12 h, and 513 
infected with H7N9 virus (at 1 MOI). After 12 h infection, cells were lysed with lysis 514 
buffer and incubated with in vitro transcribed 2 pM biotin-labeled viral RNAs for 4 h 515 
followed by incubation with pre-washed Dynabeads M-280 Streptavidin (Sigma) for 3 516 
h at 4°C. Beads were washed five times with NT2 buffer (50 mM Tris-HCl pH 7.0, 517 
150 mM NaCl, 1 mM MgCl2, 0.05% NP-40); protein complex bound to the beads was 518 
then boiled with 20 μL PBS at 100°C for 10 min. Pulled-down proteins were 519 
identified by LC-MS. 520 
Western blotting 521 
Western blotting was performed as previously described49. Briefly, protein 522 
samples were mixed with loading buffer supplemented with 10% β-mercaptoethanol, 523 
heated at 95°C for 5 min, and separated on a 10% SDS-PAGE under reducing 524 
conditions. After electrophoresis, protein samples were electroblotted onto 525 
polyvinylidene difluoride (PVDF) membranes (BioRad), and blocked for 2 h in 526 
Tris-buffered saline (10 mM Tris-HCl, pH 8.0, containing 150 mM NaCl) containing 527 
5% (w/v) non-fat dry milk and 0.5‰ (v/v) Tween-20. The blots were incubated with 528 
25 
 
the primary antibodies overnight at 4°C. The next day, the blots were incubated with 529 
corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 h 530 
at room temperature (RT). HRP antibody binding was detected using a standard 531 
enhanced chemiluminescence (ECL) kit (Thermo Scientific).  532 
Quantitative real-time RT-PCR (RT-qPCR) 533 
Total RNA from virus-infected cells or lung tissues was extracted using an RNA 534 
isolation kit (Thermo Scientific). First-strand cDNA was synthesized from 1 μg of 535 
total RNA using TransScript RT reagent Kit (TransGen). Uni-12 primer was used for 536 
the detection of influenza viral RNA and oligo dT and random primers were used for 537 
detecting host and viral genes. Generated cDNA was subjected to qPCR in a 25 μL 538 
reaction volume using FastStart Universal SYBR Green Master mix (Roche, China). 539 
Human β-actin and mouse GAPDH genes were amplified for normalization of the 540 
cDNA amount used in qPCR. Reactions were conducted in triplicates, and the data 541 
were analyzed using the 2−ΔΔCt method. qPCR primers used in this study are listed in 542 
Table S1. 543 
Type I Interferons bioassay 544 
During PR8 virus infection, IFN-I released in human cell culture media was 545 
quantified in2fTGH-ISRE cells as previously described52. In brief, 200 mL of cell 546 
culture supernatants were incubated with confluent 2fGTH-ISRE-Luci cells in 547 
24-well plate for 6 h. Cells were then lysed in passive lysis buffer and subjected to 548 
luciferase quantification (Promega). A serial dilution of recombinant human IFN-β 549 
(Invitrogen) was used as reference. 550 
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Luciferase reporter assays 551 
HEK293 cells seeded on 24-well plates were co-transfected with 125 ng of the 552 
luciferase reporter plasmids and equal amount of various expression plasmids or 553 
empty controls. Ten ng of pRL-TK plasmids were used as an internal control. After 24 554 
h of transfection, Rluc and Fluc expression were measured in the presence or absence 555 
of virus stimulation for 12 h using the Dual-Luciferase Reporter Assay kit (Promega) 556 
in a TD-20/20 Luminometer according to the manufacturers’ recommendations. 557 
Results were normalized to corresponding control reporter constructs.  558 
Gaussia Luciferase reporter assays were performed according to standard 559 
procedures described in detail elsewhere48. Briefly, HEK293T-Gluc cells were 560 
transfected with either IFI16-Flag or Flag control plasmids, followed by infection 561 
with PR8 virus (MOI = 1) for 24 h, and viral infectivity was evaluated by the Gluc 562 
activity. After a further incubation of 24 h, cell supernatants were collected and 563 
measured for Gluc activity. Dimethyl sulfoxide (DMSO) was used as negative 564 
controls. The inhibition rate of the tested compounds was calculated with the 565 
following equation, where RLU indicates relative light unit: 566 
Inhibition rate = (RLU infected cells – RLU tested compound) / (RLU infected cells -  567 
RLU mock-infected cells) 100% 568 
Histology 569 
WT and p204-/- mice were euthanized and sacrificed at the indicated time points 570 
after PR8 virus infection. Lung tissues were harvested and fixed with 4% 571 
formaldehyde, followed by paraffin embedding. For histopathological analysis, 5- to 572 
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7-μm sections were sectioned longitudinally through the left and right lung and 573 
stained using a standard hematoxylin and eosin (H&E) protocol.  574 
Immunohistochemistry 575 
Lung sections were deparaffinized with xylene and rehydrated with ethanol 576 
gradations and water. Endogenous peroxidase activity was blocked using 3% 577 
hydrogen peroxide in methanol. PBS containing 0.05% Tween-20 was used to wash 578 
lung tissue sections in between steps. Lung sections were incubated with the primary 579 
anti-NP antibody (ab20343) at a 1:100 dilution or with the isotype control at the same 580 
concentration at 4°C overnight in a humidified chamber. Sections were subsequently 581 
incubated with the horseradish peroxidase-conjugated secondary antibody for 60 min 582 
at RT. Immunodetection was performed using the Vector Elite ABC Kit (Vectastain, 583 
Vector).  584 
Co-immunoprecipitation (Co-IP) 585 
For Co-IP assays, A549 cells were infected with PR8 virus at an MOI of 5. After 586 
infection, cell samples were collected and lysed in 800 μL of IP lysis buffer (Thermo 587 
Scientific) containing protease and phosphatase inhibitors. A portion of each whole 588 
cell lysate sample was kept to confirm protein expression levels, and 500 μg of cell 589 
lysates were used for Co-IP assays. Lysates were incubated with anti-IFI16, 590 
anti-RIG-I or IgG antibodies overnight at 4°C under constant rotation, and then 40 μL 591 
of protein A/G beads (Santa Cruz) were added and incubated for 2 h at 4°C under 592 
gentle rotation. The beads were then washed four times with cold lysis buffer, and 593 
analyzed by SDS-PAGE and Western blotting. 594 
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RNA immunoprecipitation-qPCR (RIP-qPCR) 595 
Two 10-cm2 dishes (107 cells per dish) of A549 cells were infected with PR8 596 
virus for 12 h. Cells were lysed with RIP lysis buffer (50 mM HEPES, 150 mM KCl, 597 
2 mM EDTA, 1 mM NaF, 0.5% NP40, 0.5 mM DTT, 1× protease inhibitor cocktail, 598 
25 units RNasin) for 30 min at 4°C. Cell lysates were centrifuged at 12,000 rpm for 599 
15 min at 4°C and the supernatants were subjected to RNA immunoprecipitation. A 50 600 
μL aliquot of cell supernatant was saved as input, and the remaining samples were 601 
each incubated with 5 μg anti-IFI16 antibody or IgG antibody and 40 μL protein A/G 602 
beads for 10 h at 4°C under gentle shaking. After IP, the beads were pelleted and 603 
washed four times with RIP wash buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM 604 
MgCl2, 0.05% NP40), resuspended in 250 mL of DNase digestion buffer (40 mM Tris 605 
pH 8.0, 10 mM MgSO4, 1 mM CaCl2), and treated with 25U RNasin (Promega) and 606 
2U DNase I (NEB) at 37°C for 20 min. Beads were then washed and resuspended in 607 
100 μLL RIP wash buffer, 10% of each sample was removed for immunoblot analysis. 608 
And samples were treated with 4U proteinase K at 55°C for 30 min. The input and 609 
immunoprecipitated RNAs were isolated by 1 mL of TRIzol reagent (Sigma), and 610 
viral RNAs were analyzed by RT-qPCR or RNA-seq.  611 
Chromatin Immunoprecipitation-qPCR (ChIP-qPCR) 612 
Approximately 107 treated cells were cross-linked with 1% formaldehyde at RT 613 
for 10 min, and the cross-linking was quenched with 0.125 M glycine for 5 min. Cells 614 
were then collected by centrifugation, lysed with SDS lysis buffer containing protease 615 
inhibitor cocktail, and sonicated to shear the DNA. The sonicated DNA-Protein 616 
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complexes were incubated with anti-IFI16 (Cell Signaling Technology, #D8B5T), 617 
RNA pol-II (abcam, ab5095), or control IgG (Beyotime, #A7016) antibodies. The 618 
immuno complexes were collected using Protein G Dynabeads (10004d, Invitrogen). 619 
The Dynabeads were washed one time with wash buffer A (20 mM Tris-HCl (pH 8.0), 620 
500 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-100), one time with wash 621 
buffer B (10 mM Tris-HCl (pH 8.0), 250 mM LiCl, 1 mM EDTA, 1%NP-40), and 622 
three times with wash buffer C (1 mM EDTA, 10 mM Tris-HCl, pH 8.0). The beads 623 
were eluted with 100 mL elution buffer (50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 1% 624 
SDS), followed by incubation at 65°C overnight to reverse cross-linking. The next day, 625 
the DNA was purified with QIAquick PCR purification kit (Magen, D211102) and 626 
analyzed using FastStart Universal SYBR Green Master mix (Roche, China).  627 
Confocal microscopy  628 
A549 or HEK293 cells on coverslips were washed twice with pre-warmed PBS 629 
and fixed with 4% paraformaldehyde for 15 min at RT. Cells were subsequently 630 
permeablized with immunostaining permeabilization buffer containing Triton X-100 631 
(Beyotime Biotechnology) for 10 min and blocked in QuickBlock™ Blocking Buffer 632 
for 20 min at RT. Fixed cells were incubated with indicated antibodies diluted in 633 
immunostaining primary antibody dilution buffer at 4°C overnight. Coverslips were 634 
then washed three times with PBS and incubated with Alexa Fluor 488-conjugated 635 
secondary antibodies or Alexa Fluor 555-conjugated secondary antibodies for 1 h at 636 
37°C. Coverslips were finally washed three times and mounted onto microscope 637 
slides with DAPI Staining Solution (Beyotime Biotechnology) for 8 min and 638 
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examined by confocal microscopy. Immunostained cells were visualized using the 639 
Nikon Super-resolution laser scanning confocal microscope under a 100-time oil 640 
objective and analyzed by the Imaris 9.2 platform. 641 
In situ proximity ligation assay (PLA) microscopy 642 
A DuoLink PLA kit (#DUO92105-1KT, Sigma) was used to test protein-protein 643 
interactions as described in the protocol. WT or IFI16-/- A549 cells were infected with 644 
PR8 virus at 1.0 MOI for 12 h, fixed and permeabilized as described in the confocal 645 
microscopy section and blocked with DuoLink blocking buffer for 30 min at 37°C. 646 
Cells were incubated with corresponding primary antibodies diluted in DuoLink 647 
dilution buffer. After washing, cells were incubated with species-specific PLA probes 648 
(Plus and Minus) for 1 h at 37°C under hybridization conditions and in the presence 649 
of 2 additional oligonucleotides to facilitate hybridization of PLA probes if they were 650 
in close proximity (<40 nm). Ligase was then added and incubated for 30 min at 37°C 651 
to join hybridized oligonucleotides. Amplification polymerase was added to generate 652 
a concatemeric product extending from the oligonucleotide arm of the PLA probe. 653 
Finally, a detection solution consisting of fluorescence-labeled oligonucleotides was 654 
added, and the labeled oligonucleotides were hybridized to the concatemeric products. 655 
Nuclei was stained with Duolink in situ mounting medium containing DAPI. 656 
Ubiquitination assay 657 
HEK293 cells were transfected with plasmids encoding RIG-I-Flag, TRIM25-His 658 
with or without coexpression of IFI16-Myc or Myc empty vectors, and HA-Ubiquitin 659 
(WT) or HA-Ubiquitin mutants (K48 or K63). After 24 h transfection, cells were 660 
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harvested and lysed in RIPA buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% 661 
NP-40, 0.1% SDS, and 1 mM EDTA) containing protease inhibitor cocktail and 662 
10 µM deubiquitinase inhibitor N-ethylmaleimide (NEM, Sigma). The cell extracts 663 
were immunoprecipitated with anti-Flag antibody overnight at 4°C and then beads 664 
were added to the samples for 1-1.5 h at 4°C. The beads were washed three times with 665 
RIPA buffer and analyzed by immunoblotting with anti-HA antibody. 666 
RNA fluorescence in situ hybridization (RNA FISH) 667 
A549 cells were grown in 24-well slide chambers and infected with PR8 at an 668 
MOI of 1. At 12 hpi, cells were fixed for 15 min in 4% PFA, then permeablized and 669 
dehydrated by sequential 3 min incubations as follows: once with 70% ethanol, once 670 
with 85% ethanol, and three times with 100% ethanol. Cells were then hybridized 671 
with the Alexa Fluor® 488-conjugated NP RNA target probes (NP-probes, 672 
GenePharma) of PR8 virus in hybridization buffer for 10 min at 75°C. Cells were 673 
further incubated for 12-16 h at 37°C. Finally, cells were stained with anti-IFI16 and 674 
secondary antibodies, and the nuclei was stained with DAPI as previously described.  675 
Microscale thermophoresis technology (MST) 676 
HEK293 cells were separately transfected with the HINa-GFP, HINb-GFP, and 677 
PYRIN-GFP expression vectors. After 24 h of transfection, cell lysates were collected 678 
and incubated with two-fold serial dilutions of indicated viral RNAs in 679 
MST-optimized buffer at a constant concentration (20-100 nM). Equal volumes of 680 
binding reactions were mixed by pipetting and incubated for 15 min at RT. Mixtures 681 
were enclosed in standard-treated glass capillaries and loaded into the instrument 682 
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(Monolith NT.115, NanoTemper, Germany). To identify whether IFI16 directly binds 683 
to the IAV RNAs, the transcribed RNAs were labeled with fluorescein RNA labeling 684 
mix (#41027920, Sigma) and purified as previously described. Purified GST-IFI16 685 
proteins (Abcam, ab158724) were incubated with different amounts of IAV full-length 686 
fluorescein labeled RNAs, followed by MST assays. For all the measurements, 687 
200-1000 counts were obtained for the fluorescence intensity. Kd values were 688 
determined with the NanoTemper analysis tool. 689 
RNA pull down assay 690 
HEK293 cells were transfected with Flag-tagged RIG-I, IFI16, TBK1 or MAVS 691 
vectors. After 24 h transfection, cells were collected and lysed with lysis buffer (50 692 
mM Tris-HCl pH 7.0, 150 mM NaCl, 1 mM MgCl2, 0.05% NP-40). Cell lysates were 693 
mixed with transcribed biotin-labeled viral NP RNA for 4 h at 4°C and incubated with 694 
pre-washed Dynabeads M-280 Streptavidin (Sigma) for another 3 h at 4°C. The 695 
protein samples bound to the beads were boiled and analyzed by SDS-PAGE and 696 
Western blotting. 697 
DNA pull down assay 698 
IFI16 proteins were purified from IFI16-Flag overexpressing HEK293 cells by 699 
immunoprecipitation using M2 beads (Sigma). Biotinylated mutant DNA probes were 700 
synthesized by an EMSA Probe Biotin Labeling Kit (Beyotime, #GS008) and were 701 
annealed and incubated with the purified Flag-tagged IFI16 proteins for 30 min in 702 
binding buffer (10 mM Tris, 1 mM KCl, 1%NP-40, 1 mM EDTA, 5% glycerol) at RT. 703 
Then, 40 μL prewashed Dynabeads M-280 Streptavidin (Sigma) were added for 704 
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incubation at 4°C for 1 h. The mutant probe-binding proteins were eluted by boiling 705 
and analyzed by immunoblotting. 706 
Statistical analysis 707 
For all the bar graphs, data were shown as means ± SEM. All statistical analyses 708 
were performed using GraphPad Prism software version 7.00 (GraphPad Software 709 
Inc., USA). Kaplan-Meier method was employed for survival analysis. Differences in 710 
means were considered statistically significant at p < 0.05. And significance levels are 711 
as follow: * p < 0.05; ** p < 0.01; *** p < 0.001; NS., non-significant. 712 
Reporting Summary 713 
Further information on research design is available in the Nature Research 714 
Reporting Summary linked to this article. 715 
Data Availability 716 
Mass spectrometry proteomics data have been deposited with the 717 
ProteomeXchange Consortium via the PRIDE53 partner repository 718 
(https://www.ebi.ac.uk/pride/) with the dataset identifiers PXD020723 and 719 
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Figure legends 793 
Figure 1. IFI16 is induced by IAV infection and involved in the pathogenesis of 794 
virus infection. 795 
(A) Schematic representation of the viral RNA pull down-MS approach to identify 796 
viral RNA-binding proteins in THP-1 cells. (B) Protein domain types significantly 797 
enriched  among the human interacting proteins with indicated vRNA baits. The 798 
value range of Q value is [0,1]. The closer it is to zero, the more significant the 799 
enrichment is. Domains with Q ≤ 0.05 are defined as domains that are significantly 800 
enriched in differentially genes. (C) mRNA expression levels, determined by 801 
RT-qPCR, of 70 candidate viral RNA-binding proteins in THP-1 cells infected with 802 
PR8 virus at 2.0 MOI. RNA samplings were taken at 0, 6, 12 and 24 hpi. (D) IFI16 803 
protein expression in PR8 virus-infected (1.0 MOI) A549 cells was evaluated by 804 
Western blotting at 0, 6, 12, 18 and 24 hpi. β-Actin detection used as loading control. 805 
(E) Intracellular localization of IFI16 was assessed in PR8 virus-infected A549 cells at 806 
0, 6, 12 and 18 hpi by confocal microscopy. Scale bars, 5 μm. (F) Quantification of 807 
intracellular localization of IFI16 in cells as in E. The data represent means ± SD. 808 
(n= 3 independent experiments). (G) A549 cells were infected with PR8 virus at 0, 12 809 
and 24 hpi. Cell lysates were then immunoprecipitated with anti-IFI16. Bound 810 
proteins were analyzed by immunoblots with anti-acetylated lysine. (H) A549 cells 811 
were pre-incubated with C-646 for 2 h, infected with PR8 virus for 1 h, washed with 812 
PBS and incubated in complete medium with or without C-646. In situ PLA assay 813 
used to assess acetylation of IFI16 with anti-IFI16 and anti-acetylated lysine 814 
antibodies on 24 hpi. Scale bars, 28.7 μm (top) and 14.6 μm (bottom). (B): the results 815 
were assessed using a parametric paired t-test (Student’s one-tailed t-test). (D) to (H): 816 
Data presented are representative of three independent experiments. Statistical 817 
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significance in (F) was determined by unpaired two-tailed Student’s t-test. 818 
Figure 2. IFI16 expression inhibits IAV infection in vitro. 819 
(A) A549 cells were transfected with IFI16-Flag plasmids or control for 24 h and then 820 
infected with PR8 virus at 1.0 MOI for 18 h. Viral titers were measured by TCID50 821 
assay. Data presented as means ± SEMs and are representative of three independent 822 
experiments. (B) A549 cells were transfected with IFI16-Flag plasmids or control for 823 
24 h and then infected with PR8 virus at 1.0 MOI. NP and M1 proteins were detected. 824 
Data were quantified and shown as the ratio of NP to β-actin and M1 to β-actin (right), 825 
the data represent means ± SEMs (n = 3). (C) HEK293T-Gluc cells were transfected 826 
with different amounts of IFI16-Flag or control, followed by infection with PR8 virus 827 
(MOI = 1) for 24 h. Viral infectivity was determined. Data presented as means ± 828 
SEMs and are representative of three independent experiments. (D) Viral titers in PR8 829 
virus-infected (1.0 MOI) IFI16+/+ and IFI16-/- A549 cells were measured by TCID50 830 
assay. Data presented as means ± SEMs and are representative of three independent 831 
experiments. (E) The NP and M1 protein expression in 1 MOI of PR8 virus-infected 832 
IFI16+/+ and IFI16-/- A549 cells was analyzed. Data were quantified and shown as the 833 
ratio of NP to β-actin and M1 to β-actin (right), the data represent means ± SEMs (n 834 
= 3). (F) IFI16+/+ and IFI16-/- A549 cells were transfected with IFI16-Flag plasmids or 835 
empty control for 24 h and then infected with PR8 virus at 1.0 MOI. NP and M1 836 
proteins in virus-infected A549 cells was detected. Data were quantified and shown as 837 
the ratio of NP to β-actin and M1 to β-actin (right) the data represent means ± SEMs  838 
(n = 3). (G) Fluorescence microscopy images of viral replication (green) in IFI16+/+ 839 
and IFI16−/− A549 cells after infection with GFP-PR8 virus for 12 h. Scale bar, 840 
200 μm. (B) and (D) to (G): data are representative of three independent experiments. 841 




Figure 3. p204-deficient mice are susceptible to IAV infection.  844 
(A) WT and p204-/- mice (n = 6) were infected with 50 TCID50 of PR8 virus. Changes 845 
in body weight were monitored daily. Data presented as means ± SD. (B) Survival of 846 
WT and p204-/- mice infected with 50 TCID50 of PR8 virus. Data presented were 847 
pooled from three independent experiments. Kaplan-Meier Survival Curves were 848 
compared using the log-rank (Mantel-Cox) analysis. (C) Viral titers in lung tissues 849 
from 50 TCID50 of PR8 virus-infected WT and KO mice at 4 and 6 dpi were 850 
determined by EID50 assay. Data are from three independent experiments with n = 6 851 
mice per group run in triplicate. Error bars indicate SEM. (D) Viral NP mRNA and 852 
vRNA in lung tissues of PR8 virus-infected WT and KO mice at 3 dpi were 853 
determined by RT-qPCR. Data presented as means ± SEMs and are representative of 854 
three independent experiments. (E) Viral NP protein expression in lung tissue sections 855 
from virus-infected WT and KO mice (n =3) mice was examined by 856 
immunohistochemistry. Representative sections of one mouse out of three are shown. 857 
Scale bars, 800 μm (top) and 80 μm (bottom). (F) Gross lesion of lung tissues from 858 
virus-infected WT and p204-/- mice at 3 and 5 dpi. Representative sections of one 859 
mouse out of three are shown. (G) H&E staining of lung tissues from virus-infected 860 
WT and p204-/- mice at 3 dpi. Scale bars, 600 μm (left) and 120 μm (right). 861 
Representative of H&E staining images from 6 mice per group of three independent 862 
experiments. (H) to (I): IL-6 and MCP-1 levels in BALF from virus-infected WT and 863 
KO mice (n = 4) were quantified. Data are presented as means ± SD. (J) to (N) mRNA 864 
expression of IFN-β, viperin, OAS1, ISG15, and IL-6 in BMDMs of virus-infected 865 
WT and KO mice was determined by RT-PCR. Data presented as means ± SEMs and 866 
are representative of three independent experiments. Statistical significance in (A), (C) 867 
40 
 
to (D) and (H) to (N) was determined by unpaired two-tailed Student’s t-test. ns = 868 
non-significant. 869 
Figure 4. IFI16 enhances RIG-I-mediated production of IFN-I during IAV 870 
infection.  871 
(A) GO-term analysis of up-regulated host proteins in IAV-infected IFI16+/+ and 872 
IFI16-/- A549 cells. Top 10 GO-terms ordered by enrichment p-values are shown. 873 
p-values as indicated in legend and indices in cells correspond to number of protein 874 
groups associated to individual GO-terms in respective comparison. (B) Differential 875 
expression of host genes between IAV-infected and mock conditions in IFI16+/+ (X 876 
axis) and IFI16-/- (Y axis). Proteins exhibiting significant differential response are 877 
highlighted in green (ISGs) or yellow (non-ISGs). (C) to (F): Gene expression of 878 
IFN-β (C), RIG-I (D), ISG56 (E), viperin (F) in PR8 virus-infected IFI16+/+ and 879 
IFI16-/- A549 cells at 0, 6, and 12 hpi was determined by qPCR. (G) A549 cells were 880 
transfected with IFI16-Flag expression vectors or empty vector for 24 h and then 881 
infected with PR8 virus. IFN-I in supernatants were quantified IFN-bioassay at 2, 12, 882 
18, 24 and 36 hpi from 1.0 MOI infection. (H) IFI16+/+ and IFI16-/- A549 cells were 883 
infected with PR8 virus at a 1.0 MOI. IFN-I in supernatants were then measured by 884 
IFN-bioassay at 2, 12, 18, 24 and 36 hpi. (I) A549 cells were transfected with 885 
IFI16-Flag expression vectors or empty control for 24 h and then infected with 1.0 886 
MOI of PR8 virus for 0, 2, 4, 8 and 12 h. RIG-I triggered downstream signaling 887 
molecules were evaluated with indicated antibodies. (J) RIG-I triggered downstream 888 
signaling molecules in PR8 virus-infected IFI16+/+ and IFI16-/- A549 cells at 0, 4, 8, 889 
and 12 hpi were analyzed with indicated antibodies. (K) IFI16+/+ and IFI16-/- A549 890 
cells were infected with PR8 virus at 5.0 MOI. Nuclear localization of p-IRF3 was 891 
then determined by p-IRF3 (Ser396)  intracellular immunostaining for confocal 892 
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microscopy. Scale bar represents 10 μm. (L) Quantification of nuclear localization of 893 
p-IRF3 (Ser396).(I) to (K): Data are representative of three independent experiments.  894 
(A): the results were assessed using a parametric paired t-test (Student’s one-tailed 895 
t-test). (C) to (H) and (L): Data presented as means ± SD from three independent 896 
experiments, and the significance of the results was assessed using a parametric 897 
paired t-test (Student’s two-tailed t-test). ns = non-significant                        898 
Figure 5. IFI16 upregulates RIG-I expression. 899 
(A) RIG-I expression in IFI16-Flag overexpressing A549 cells at 0, 18, 24, and 30 h 900 
post-transfection was detected by Western blotting. β-Actin detection was used as 901 
loading control. (B) RIG-I mRNA expression in A549 cells transfected with 902 
IFI16-Flag plasmids for 0, 12, 18 and 24 h was quantified by RT-qPCR. (C) 903 
Luciferase activity of RIG-I reporter in HEK293 cells transfected with increasing 904 
amounts of FI16-Flag expression vectors for 24 h. Luciferase levels were normalized 905 
to Renilla levels. Values shown are fold changes over empty vector control. (D) 906 
Schematic diagram of 2000 bp promoter sequence of RIG-I gene and corresponding 907 
mutants. (E) HEK293 cells were co-transfected with the RIG-I promoter mutant 908 
constructs and increasing amounts of IFI16-Flag as indicated. Luciferase levels were 909 
normalized to Renilla values. Values shown as fold change over empty vector control. 910 
(F) to (G): Schematic diagram of part of the RIG-I promoter sequence and every 50 911 
bp-deletion mutants, and luciferase reporter assay on the truncated mutants was 912 
performed as the described in (E). (H) to (I): Schematic diagram of part of the RIG-I 913 
promoter sequence and every 10 bp-deletion mutants, and luciferase reporter assay of 914 
these truncated mutants was performed as the described in (E). (J) A549 cells were 915 
infected with PR8 virus for 12 h followed by ChIP assay. The promoter sequence 916 
binding to the IFI16 was determined by RT-qPCR. (K) IFI16+/+ and IFI16-/- A549 917 
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cells were infected with PR8 virus for 0 and 12 h, followed by ChIP assay. RNA Pol II 918 
recruitment to RIG-I promoter was assessed by RT-qPCR. Data presented as percent 919 
input minus IgG background. (L) Luciferase activity of RIG-I promoter-luciferase 920 
reporter in HEK293 cells transfected with full-length IFI16 vectors and truncated 921 
mutant plasmids. Luciferase levels were normalized to Renilla values. Values shown 922 
as fold change over empty vector control. (A): Data are representative of three 923 
independent experiments. (B) to (L): Data presented as means ± SD from three 924 
independent experiments. Statistical significance in (B) to (C) and (E) to (L) was 925 
determined by unpaired two-tailed Student’s t-test. ns = non-significant. 926 
Figure 6. IFI16 binds viral RNA and associates with RIG-I protein  927 
(A) Co-localization of endogenous IFI16 (green) and viral NP RNA (red) in PR8 928 
virus-infected A549 cells at 0, 6, and 12 hpi was detected by RNA FISH. Nuclei were 929 
stained with DAPI (blue). Scale bars, 10 μm. Quantification of the co-localization of 930 
IFI16 and NP RNA in cells (bar plots). Means ±SD from 3 biological samples. (B) 931 
Integrated Genome Viewer representation of captured IAV genomic (negative polarity) 932 
reads from Flag-immunoprecipitations of PR8-infected RIG-I-/- cells overexpressing 933 
IFI16-Flag (top) or RIG-I-Flag (bottom). Each horizontal green bar represents a single 934 
150 nt read and the position where it aligns relative to an IAV gene segment. (C) PCR 935 
detection of PB2 vRNAs in eluted RNA from RIG-I-Flag, IFI16-Flag and indicated 936 
Flag-tagged IFI16 deletions. (D) A549 cells were infected with PR8 virus at 5.0 MOI 937 
for indicated duration, followed by co-immunoprecipitation with anti-IFI16 or IgG 938 
and immunoblotting analysis with anti-RIG-I antibody. (E) A549 cells were infected 939 
with PR8 virus at 5.0 MOI for indicated duration, followed by 940 
co-immunoprecipitation with anti-RIG-I or IgG and immunoblotting analysis with 941 
anti-IFI16 antibody. (F) A549 cells were infected with 1.0 MOI of PR8 virus and then 942 
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analyzed by PLA with anti-IFI16 and anti-RIG-I antibodies at 0, 12 and 24 hpi. The 943 
right panels are enlarged. Red point indicates IFI16 plus RIG-I complexes, green 944 
point indicates the viral M1 protein. Scale bars, 60 μm (left), 10 μm (right). Data 945 
presented are representative of three independent experiments. 946 
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